Yan [ph]'s questions to Kezar Life Sciences (KZR) leadership • Q2 2020
Question
Yan of Wells Fargo asked about the mechanism behind the UPCR reduction seen in the MISSION study, changes to the trial's enrollment criteria and potential label implications, and the enrollment status of the now-discontinued MARINA study.
Answer
President & CSO Christopher Kirk detailed that KZR-616 showed reductions in pathogenic autoantibodies and inflammatory gene modules, suggesting a broad immunomodulatory effect. Chief Medical Officer Noreen Henig added that the amended MISSION criteria are more reflective of real-world practice, which could support a broader label. She reiterated that no patients were ever enrolled in the MARINA study due to its overly restrictive protocol.